PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
The aim – assess the clinical advantages and economic burden of various treatment strategies in patients with hemophilia A in the Russian Federation and propose the ways of optimizing this area of medical care.Materials and methods. A mathematical model describing the current (2017) approach to ther...
Saved in:
Main Authors: | M. Yu. Frolov, V. A. Rogov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2018-02-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/212 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01) -
Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01) -
PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01) -
Clinical Characteristics of Hemophilia Today
by: M. Y. Ledyaev, et al.
Published: (2010-06-01)